Please login to the form below

Not currently logged in

Nycomed expands in China

Swiss pharma company Nycomed acquires majority stake in Guangdong Techpool Bio-Pharma

Nycomed is expanding its presence in China through the acquisition of a majority stake (51.34 per cent) in Guangdong Techpool Bio-Pharma Co (Techpool), a Chinese bio-pharmaceutical company.

Techpool, founded in 1993, specialises in the research, development, manufacturing and marketing of biologic drugs derived from natural sources. Its portfolio includes innovative protein drugs Ulinastatin, a broad-acting trypsin inhibitor, for the treatment of sepsis and multiple organ dysfunctions and Kallikrein, a serine protease, which is used in the treatment of stroke.

Techpool has a strong intellectual property position, including 35 patents filed, of which 17 have been granted, including one US patent approval.

Shanghai Pharmaceutical Group, a Chinese pharmaceutical conglomerate, holds 40.8 per cent of the shares of Techpool and was previously the majority shareholder.

Nycomed believes there is significant potential for continued strong growth of Techpool's key products through expanded hospital and reimbursement coverage in China. While Nycomed China and Techpool will be run as separate companies, value will be created through various alliances between them. The two companies will continue to expand in China, focusing on five core brands: Ulinastatin, Kallikrein, Pantoloc, Ebrantil and Actovegin.

Håkan Björklund, CEO of Nycomed, said: "Techpool's speciality franchise is highly complementary to Nycomed's development strategy and will become a cornerstone of our international expansion in emerging markets."

Techpool's management team, headed by the founder and CEO Dr Fu, will play a pivotal role in Nycomed's future expansion and the alliance has the support of Techpool's existing shareholders, including Shanghai Pharmaceutical Group.

Techpool has a marketing network spanning the whole of China and its products are distributed throughout Japan, South Korea, India and Pakistan, among other countries.

Nycomed has branded medicines in gastroenterology, respiratory and inflammatory diseases, pain, osteoporosis and tissue management, along with a range of OTC products.

2nd November 2010


Subscribe to our email news alerts

Featured jobs


Add my company
Aptus Health

Aptus Health is dedicated to advancing health engagement. The company offers end-to-end digital health engagement solutions spanning all areas of...

Latest intelligence

Our Top 5 Pharma Picks From Cannes Lions
Here are five of Art's top five pharma and healthcare picks from Cannes Lions 2022....
The Evolving Role of the Sales Rep
The COVID-19 pandemic sparked an evolution in physician engagement. Jill Padgett, EdD, Head of Training, explores what this means for the sales force and shares her advice for succeeding in...
Measure your omnichannel maturity with our new tool
Try our Omnichannel Maturity Tool to gain tangible advice and an instant analysis of your omnichannel readiness....